Unlock Understanding in Renal and Urological Disorders
Identify Biomarkers and Disease Mechanism
Understand Renal & Urological Disorders through Metabolomics and Lipidomics
The Metabolon Global Discovery Panel provides a high-fidelity and reproducible analysis of the current state of a biological sample to help identify biomarkers and reveal changes in key biological pathways. Global metabolomics can be applied to cultured cells, tissues, blood plasma, and serum to discover metabolic signatures of renal and urological disorders. These insights can be translated into actionable biomarkers through follow-on targeted quantitative assays. Furthermore, patients with CKD or kidney failure have altered complex lipid metabolism2 thus, accurate identification and quantification of lipid species through the Complex Lipids Targeted Panel are essential for biomarker discovery and biological insights. Metabolon’s unmatched chemical library can identify many classes of metabolites and metabolic pathways. Global metabolomics and lipidomics offer the opportunity to profile thousands of biochemicals in an unbiased fashion to enable the discovery of novel disease mechanisms and biomarkers. Additionally, a closer look at specific pathways and metabolite classes relevant to the kidney can be achieved using Targeted Panels such as the Creatinine Single Analyte Assay or the Indoles/Uremic Toxicity Targeted Panel.
Elucidate novel biomarkers for Renal & Urological Disorders
The economic burden of CKD is substantial,3 so understanding the underlying biology behind disease pathogenesis and identifying biomarkers can help with disease prevention, detection, and assessment of treatment efficacy. Metabolomics and lipidomics are uniquely poised to drive the needed research and development to fuel greater understanding of these conditions and drive diagnostic and therapeutic opportunities. Metabolon’s reference library contains over 5,400 metabolites, and our Complex Lipids Targeted Panel can identify up to 1,100 individual lipid species, providing quantitative lipidomic analysis. Metabolomic and lipidomic profiling are unique and powerful tools that can provide insights into the molecular processes influencing renal and urological diseases. Metabolon’s deep experience in metabolomics and lipidomics can play a vital role in future advancements in the renal and urological field.
See how Metabolon can advance your path to preclinical and clinical insights
Metabolomics Panels for Renal and Urological Disorders
Complex Lipids Targeted Panel
Metabolon has overcome the challenges of lipid profiling to create the only platform able to provide both complete and quantitative lipidomic analysis.
Creatinine Single Analyte Assay
Indoles/Uremic Toxicity Targeted Panel
Metal Analysis Targeted Panel
WILLETTE ET AL. 2021
Metabolon in Action
Metabolomics Identifies Preclinical Biomarker of Acute Renal Injury
Understanding Pediatric Chronic Kidney Disease (CKD) with Metabolomics and Machine Learning
The untargeted plasma metabolomics data from this population health study represent an exciting opportunity to better understand biochemical differences based on underlying pediatric CKD causes. Identification of such differences may improve our ability to predict disease progression and associated morbidity and may identify potential therapeutic targets. This research also provides new directions for future studies of CKD.
Interested in Further Studies?
Once you see the full value of metabolomics, the only remaining question is who does it best? While many laboratories have metabolite profiling or analytical chemistry capabilities, comprehensive metabolomics technologies are extremely rare. Accurate, unbiased metabolite identification across the entire metabolome introduces signal-to-noise challenges that very few labs are equipped to handle. Also, translating massive quantities of data into actionable information is slow, if not impossible, for most because proper interpretation takes two things that are in short supply: experience and a comprehensive database.
Only Metabolon has all four core metabolomics capabilities
Ability to interrogate thousands of metabolites across diverse biochemical space, revealing new insights and opportunities
Ability to integrate the data from different studies into the same dataset, in different geographies, among different patients over time
Ability to inform on proper study design, generate high‐quality data, derive biological insights, and make actionable recommendations
Ability to process hundreds of thousands of samples quickly and cost‐efficiently to service rapidly growing demand
Partner with Metabolon to access:
A library of 5,400+ known metabolites, 2,000 in human plasma, all referenced in the context of biochemical pathways
- That’s 5x the metabolites of the closest competitor
Unparalleled depth and breadth of experience analyzing and interpreting metabolomic data to find meaningful results
- 10,000+ projects with hundreds of clients
- 2,000+ publications covering 500 diseases, including numerous peer-reviewed journals such as Cell, Nature and Science
- Nearly 40 PhDs in data science, molecular biology, and biochemistry
Using our robust platform and visualization tools, our experts are uniquely able to tell you more about your molecule and develop assay panels to help you zero in on the results you need.
Related Renal & Urological Disorders Metabolomics Resources
Talk with an expert
Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.
617 Davis Drive, Suite 100
Morrisville, NC 27560
P.O. Box 110407
Research Triangle Park, NC 27709
+1 (919) 572-1711
1. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 10 01 2019;322(13):1294-1304. doi:10.1001/jama.2019.14745
2. Baek J, He C, Afshinnia F, Michailidis G, Pennathur S. Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease. Nat Rev Nephrol. 2022;18(1):38-55. doi:10.1038/s41581-021-00488-2